EUVIMEDEUVIMED entdecken
Crossref

The functional role of ERK activity in esketamine's antidepressant effects

Peng Zhang, Mengyu Wu, Keke Zhang, Jiajing He, Xingxing Liu, Hongxing Zhang, Ankang Hu, Zhou Wu

Pharmacology Biochemistry and Behavior · 2026-10 · 267 · 174248

DOI: 10.1016/j.pbb.2026.174248 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Biochemistry and Behavior, 2026-10. Verfasst von Peng Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory Animal Center, Xuzhou Medical University, Xuzhou, 221004, China. Hauptthemen laut MEDLINE: Antidepressive Agents, Ketamine, Extracellular Signal-Regulated MAP Kinases. Die Arbeit nennt 43 Literaturangaben. Gefördert von: Jiangsu Province Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Esketamine has been approved for the treatment of treatment-resistant depression. However, there is an unmet clinical need to extend the duration of esketamine's action to reduce the high recurrence rate after drug withdrawal and the potential side effects of repeated esketamine use. Here, we found that increasing extracellular signal-regulated kinase (ERK) activity by pharmacologically inhibiting dual-specificity phosphatases 6 (DUSP6) had no antidepressant-like effects. However, when combined with 10 mg/kg esketamine, it extended esketamine's antidepressant-like effects from 7 days to 10 days in naïve mice. Regrettably, inhibition of DUSP6 does not exert a dose-sparing effect or an early onset on the behavioral effects of esketamine. Moreover, inhibiting ERK activity by using SL327 prevents the rapid and sustained antidepressant-like effects of esketamine, and SL327 alone has no significant effects. These results suggest that ERK-related signaling is essential for the rapid and sustained antidepressant-like effects of esketamine, and enhancement of ERK activity has the potential to prolong the antidepressant-like effects of esketamine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antidepressive AgentsKetamineExtracellular Signal-Regulated MAP KinasesAnimalsMiceMaleDual Specificity Phosphatase 6AminoacetonitrileMAP Kinase Signaling SystemDose-Response Relationship, Drug

Stichwörter der Autor:innen

BDNF-TrkB signaling pathwayERK activityEsketamineNMDA receptorTreatment-resistant depression

Substanzen

Antidepressive AgentsKetamineExtracellular Signal-Regulated MAP KinasesEsketamineDual Specificity Phosphatase 6SL 327Aminoacetonitrile

Autor:innen und Institutionen

  • Laboratory Animal Center, Xuzhou Medical University, Xuzhou, 221004, China.
  • School of Anesthesiology, Xuzhou Medical University, Xuzhou, Jiangsu, 221004, China; Jiangsu Province Key Laboratory of Anesthesiology, Xuzhou Medical University, Xuzhou, 221004, China; Jiangsu Province Key Laboratory o…
  • Laboratory Animal Center, Xuzhou Medical University, Xuzhou, 221004, China. Electronic address: hak@xzhmu.edu.cn.

Förderung

  • Jiangsu Province Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, P., Wu, M., Zhang, K., He, J., Liu, X., Zhang, H., Hu, A., & Wu, Z. (2026). The functional role of ERK activity in esketamine's antidepressant effects. Pharmacology Biochemistry and Behavior, 267, 174248. https://doi.org/10.1016/j.pbb.2026.174248

Vancouver

Zhang P, Wu M, Zhang K, He J, Liu X, Zhang H, et al. The functional role of ERK activity in esketamine's antidepressant effects. Pharmacology Biochemistry and Behavior. 2026;267:174248. doi:10.1016/j.pbb.2026.174248

BibTeX
@article{Zhang2026,
  author = {Zhang, Peng and Wu, Mengyu and Zhang, Keke and He, Jiajing and Liu, Xingxing and Zhang, Hongxing and Hu, Ankang and Wu, Zhou},
  title = {The functional role of ERK activity in esketamine's antidepressant effects},
  journal = {Pharmacology Biochemistry and Behavior},
  year = {2026},
  volume = {267},
  pages = {174248},
  doi = {10.1016/j.pbb.2026.174248}
}
Kostenlos starten →